Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Effects of Dapagliflozin on HDL Particles Subtypes and Reverse Cholesterol Transport in Type 2 Diabetic Patients. A 12 Weeks Randomized Placebo-controlled Phase IV Study

Next Previous
Trial Profile

The Effects of Dapagliflozin on HDL Particles Subtypes and Reverse Cholesterol Transport in Type 2 Diabetic Patients. A 12 Weeks Randomized Placebo-controlled Phase IV Study

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dapagliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms DAPA-HDL

    • Most Recent Events

    • 05 Oct 2018 Results assessing effects of sodium glucose cotransporter-2 inhibitors (dapagliflozin) on circulating stem and progenitor cells, presented at the 54th Annual Meeting of the European Association for the Study of Diabetes.
    • 02 Aug 2018 Primary endpoint (Change from baseline in reverse cholesterol transport, measured as cholesterol efflux capacity of patients plasma) has not been met, according to results published in the Journal of Clinical Endocrinology and Metabolism.
    • 02 Aug 2018 Results published in the Journal of Clinical Endocrinology and Metabolism.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top